← Back to Search

Genetic Testing for Blood Cancers

N/A

Waitlist Available

Led By Christopher Reilly, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age of 18 years or older

Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 63 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if testing healthy skin cells can help detect cancer genes in people with blood cancer. Researchers will also check how many blood cancer patients have a genetic risk for cancer based on family genes

Who is the study for?

This trial is for individuals diagnosed with blood cancers like myeloid leukemia. It aims to find out if their cancer risk comes from family genes by using a genetic test on healthy skin cells.

What is being tested?

The study is testing the feasibility of using a genetic blood test on skin cells to detect predisposition to myeloid malignancies and other related blood cancers in patients.

What are the potential side effects?

Since this trial involves only a genetic blood test, there are minimal side effects expected, primarily related to the procedure of collecting skin cells which may include slight pain or bruising.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I was diagnosed with a blood disorder or bone marrow failure in the last 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 63 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 63 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 63 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Genetic Testing Completion Rate

Incidence Rate of Positive Genetic Results

Secondary study objectives

Detection Rate of Germline Predisposition

Impact of Genetic Results on Clinical Decision-Making

Multidimensional Impact of Cancer Risk Assessment (MICRA) Score

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Germline Genetic TestingExperimental Treatment1 Intervention

Participants will be enrolled and will complete study procedures as follows: * Baseline visit with educational video and questionnaires. * Skin punch biopsy. * Genetic testing results. * Surveys and questionnaires. * Follow up via medical records for up to 2 years from time of study consent.

0 / 2Eligibility criteria met